Quest Diagnostics Inc. (NYSE:DGX) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $83.79 and last traded at $83.00, with a volume of 382,391 shares. The stock had previously closed at $83.01.

A number of brokerages have commented on DGX. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Monday. Jyske Bank cut shares of Quest Diagnostics from a “neutral” rating to a “sell” rating in a research note on Friday, June 24th. Mizuho restated a “buy” rating and set a $84.00 price target on shares of Quest Diagnostics in a research note on Friday, June 3rd. Morgan Stanley restated a “sell” rating on shares of Quest Diagnostics in a research note on Tuesday, June 7th. Finally, Credit Suisse Group AG restated a “hold” rating on shares of Quest Diagnostics in a research note on Tuesday, May 24th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $77.86.

The firm’s 50 day moving average price is $78.78 and its 200 day moving average price is $72.23. The company has a market capitalization of $11.73 billion and a price-to-earnings ratio of 16.08.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, April 21st. The company reported $1.12 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.12. The company earned $1.86 billion during the quarter, compared to analyst estimates of $1.82 billion. During the same quarter last year, the company posted $1.05 EPS. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. On average, equities research analysts expect that Quest Diagnostics Inc. will post $5.09 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 20th. Investors of record on Wednesday, July 6th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, July 1st. This represents a $1.60 dividend on an annualized basis and a yield of 1.93%.

In related news, SVP Catherine T. Doherty sold 47,334 shares of the company’s stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $77.27, for a total value of $3,657,498.18. Following the transaction, the senior vice president now owns 100,402 shares in the company, valued at approximately $7,758,062.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Catherine T. Doherty sold 29,550 shares of the company’s stock in a transaction dated Monday, April 25th. The shares were sold at an average price of $74.45, for a total transaction of $2,199,997.50. Following the completion of the transaction, the senior vice president now owns 106,285 shares in the company, valued at approximately $7,912,918.25. The disclosure for this sale can be found here.

A number of hedge funds have bought and sold shares of the stock. Gulf International Bank UK Ltd increased its stake in Quest Diagnostics by 0.6% in the fourth quarter. Gulf International Bank UK Ltd now owns 43,328 shares of the company’s stock worth $3,082,000 after buying an additional 250 shares in the last quarter. GAM Holding AG increased its stake in Quest Diagnostics by 0.6% in the fourth quarter. GAM Holding AG now owns 77,896 shares of the company’s stock worth $5,542,000 after buying an additional 427 shares in the last quarter. Krasney Financial LLC increased its stake in Quest Diagnostics by 0.5% in the fourth quarter. Krasney Financial LLC now owns 104,472 shares of the company’s stock worth $7,432,000 after buying an additional 494 shares in the last quarter. Toth Financial increased its stake in Quest Diagnostics by 1.0% in the fourth quarter. Toth Financial now owns 63,673 shares of the company’s stock worth $4,530,000 after buying an additional 654 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Quest Diagnostics by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 232,846 shares of the company’s stock worth $16,565,000 after buying an additional 740 shares in the last quarter.

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.